Q-omics provides the consensus-scored RDH10 profile across patient tissues and cancer cell-line models. RDH10 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RDH10 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RDH10 protein abundance shows 27,162 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRC, and PDAC as cancer lineages where RDH10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RDH10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RDH10 survival associations across molecular data types. RDH10 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RDH10 RNA expression–survival associations across cancer types. High RDH10 expression shows unfavorable associations in UVM, THCA, KIRP and LGG, but favorable associations in KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RDH10 RNA expression.
This table summarizes RDH10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RDH10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RDH10 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, UCEC, LIHC and LUAD. The KIRC box plot shows higher RDH10 RNA expression in normal versus tumor tissue (log2 FC = −1.423, t-test p < 0.001).
This table shows molecular features associated with RDH10 in patient tissues and cancer cell lines. In patient samples, RDH10 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RDH10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
